임상시험

BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction

NCT: NCT02876042 · COMPLETED

NCT IDNCT02876042

상태COMPLETED

시작일2017-03-23

완료2025-11-03

SponsorCVRx, Inc. (INDUSTRY)

First posted2016-08-23

Last updated2026-09-11

간략 요약

The purpose of this registry (NCT02876042) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO system in the commercial setting in subjects recently implanted under the CE-Marked indication for resistant hypertension that also have evidence of heart failure with preserved ejection fraction (HFpEF).

공식 출처

ClinicalTrials.gov에서 보기 →

데이터는 ClinicalTrials.gov API에서 제공됩니다. 최신 상태는 공식 기록을 확인하세요.